Related Experiment Videos
Tegaserod (Novartis)
1Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK. peter.norman2@btinternet.com
Idrugs : the Investigational Drugs Journal
|July 16, 2003
Summary
Tegaserod, a 5-HT(4) receptor partial agonist, was developed for irritable bowel syndrome (IBS) and other gastrointestinal disorders. Regulatory challenges, including FDA non-approval, significantly impacted its market potential and sales forecasts.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Tegaserod is a 5-HT(4) receptor partial agonist developed by Novartis.
- It was intended for treating constipation-predominant irritable bowel syndrome (IBS) and other functional gastrointestinal disorders like GERD, chronic constipation, and functional dyspepsia.
Purpose of the Study:
- To document the development, launch, and market projections of tegaserod.
- To track the impact of regulatory decisions on the commercial outlook of tegaserod.
Main Methods:
- Review of product launch timelines and geographical approvals.
- Analysis of financial analyst sales forecasts and revisions.
- Documentation of regulatory events, including MAA withdrawal and NDA rejection.
Main Results:
- Tegaserod was launched in Mexico, Czech Republic, Venezuela, and Colombia for IBS starting in July 2001.
- Initial sales forecasts were optimistic, but significant downward revisions occurred following regulatory setbacks, including a US FDA 'non-approvable' letter.
- Analyst confidence in tegaserod reaching major markets diminished considerably.
Conclusions:
- Regulatory hurdles posed a substantial risk to tegaserod's market success.
- Sales projections for tegaserod were drastically reduced due to regulatory challenges and market access uncertainties.